Tecan Interim Report 2020
Then and now:
40 years of human discovery
Contents
3 Letter to the Shareholders
- Interim consolidated statement of profit or loss and other comprehensive income
- Interim consolidated balance sheet
- Interim consolidated statement of cash flows
- Interim consolidated statement of changes in equity
- Notes to the interim condensed consolidated financial statements
21 Global
Letter to the Shareholders
Dear Shareholders
Tecan saw strong demand for a number of its product lines to help in the global fight against the coronavirus pandemic, resulting in a substantial increase in sales and a surge in orders in the first half of 2020. Tecan has an important role to play in this unprecedented time, and we recognize the responsibility we have as part of the international effort to turn the tide on COVID-19. Our laboratory automation solutions and our disposable pipette tip business saw a substantial increase in demand, and we took a number of steps to expand the production capacity and supply of those product lines. At the same time, parts of our business faced significant headwinds, largely in non COVID-19 research and diagnostic testing.
This year we are celebrating Tecan's 40th anniversary. The company's purpose has always been to positively impact healthcare and the lives of all individuals, but Tecan's contribution has probably never been more apparent than during these times. We couldn't be more proud of our employees as they stepped up to the challenge presented by the COVID-19 pandemic, passionately supporting our customers in research, therapeutic and vaccine development and to an even larger degree with the scale-up of diagnostic testing.
FINANCIAL RESULTS
FOR THE FIRST HALF OF 2020
Order entry increased by 24.3% in local currencies or 20.4% in Swiss francs. At CHF 374.0 million in the first six months of the year (H1 2019: CHF 310.6 million), order entry significantly exceeded the sales realized during the reporting period. Product lines supporting the global fight against the coronavirus pandemic saw a substantial increase in demand and, as a result, the order backlog again grew significantly to reach a record high as of June 30, 2020.
Sales climbed by 8.0% in local currencies or 4.7% in Swiss francs to CHF 310.0 million in the first half of the year (H1 2019: CHF
296.1 million). Demand for product lines used in the context of the coronavirus pandemic more than offset weaker sales trends in oth- er areas of the portfolio, which were adversely affected by lockdowns as customers closed or restricted access to their facilities. Both busi- ness segments were impacted by this overall demand pattern and experienced pronounced headwinds and tailwinds.
Demand for pipette tips increased drastically due to the testing needs associated with COVID-19. As a result, overall recurring sales of services, consumables and reagents also increased in the first half
of 2020 by 13.9% in local currencies and 9.9% in Swiss francs, thus amounting to 46.6% of total sales (H1 2019: 44.4%).
The reported operating profit before depreciation and amortization (earnings before interest, taxes, depreciation and amortization; EBITDA) rose to CHF 60.2 million in the reporting period (H1 2019: CHF 49.3 million). With an increase of 22.0%, reported EBITDA grew faster than sales due to several positive factors: 1.) as development projects progressed and neared product launch, more development costs were capitalized and were not recognized in research and development expenses, 2.) several operating cost items were lower, delayed or will be shifted to the second half of the year due to lockdown measures associated with the COVID-19 pan- demic, 3.) an adjustment of the Swiss pension plan resulted in a one-time positive effect from past service costs. In addition, the reported EBITDA margin of the prior-year period included non- recurring costs of around 90 basis points. Acquisition-related costs for completed acquisitions were comparable in both periods. The reported EBITDA margin grew correspondingly to 19.4% of sales in the first half of 2020 (H1 2019: 16.6%).
Tecan Interim Report 2020 | 3 |
Letter to the Shareholders
DR. LUKAS BRAUNSCHWEILER | DR. ACHIM VON LEOPRECHTING |
Chairman of the Board | Chief Executive Officer (since April 2019) |
Reported net profit in the first half of 2020 rose by 42.2% to CHF
36.0 million (H1 2019: CHF 25.3 million). Thanks to a lower tax rate in connection with the tax reform in Switzerland, net profit increased by more than operating profit (earnings before interest and taxes; EBIT). The net profit margin amounted to 11.6% of sales (H1 2019: 8.6%). Earnings per share rose strongly to CHF 3.02 (H1 2019: CHF 2.14).
Cash flow from operating activities more than doubled due to a focus on cash collection and management and reached CHF 82.8 million in the first half of 2020 (H1 2019: CHF 36.0 million), corresponding to 26.7% of sales (H1 2019: 12.1%).
INFORMATION BY BUSINESS SEGMENT
LIFE SCIENCES BUSINESS (END-CUSTOMER BUSINESS)
Sales in the Life Sciences Business increased by 4.3% to CHF 169.4 million (H1 2019: CHF 162.4 million) in the first half of the year and were 9.0% above those of the prior-year period in local curren- cies. The Life Sciences Business experienced strong demand for products supporting the COVID-19 response, mainly liquid handling and automation workstations as well as the associated disposable pipette tips.
However, parts of the Life Sciences Business also experienced significant disruption as customer facilities were closed or access was restricted to slow the spread of COVID-19. Product groups adversely impacted included detection instruments, research reagents for next-generation sequencing (NGS) and consumables for mass spectrometry sample preparation.
Order entry in the Life Sciences Business outpaced recognized revenues significantly in the first half of the year, with order backlog increasing at a substantial double-digit rate.
Despite continued acquisition-related costs, operating profit in this segment (earnings before interest and taxes; EBIT) rose to CHF 22.5 million (H1 2019: CHF 19.0 million). The operating profit margin was 12.6% of sales (H1 2019: 11.2%).
PARTNERING BUSINESS (OEM BUSINESS)
The Partnering Business generated sales of CHF 140.6 million in the period under review (H1 2019: CHF 133.7 million), which corresponds to an increase of 6.8% in local currencies and 5.2% in Swiss francs. Similar patterns to those in the Life Sciences Business were observed in the Partnering Business, with automation platforms, OEM components and disposable pipette tips to support COVID-19 testing being in high demand. By contrast, sales to customers exposed to other areas of routine diagnostics were adversely impacted.
4 Tecan Interim Report 2020
Letter to the Shareholders
Order entry growth also outpaced sales development in the Partnering Business, with the order backlog increasing at a double-digit rate.
Operating profit in this segment (earnings before interest and taxes; EBIT) increased to CHF 26.3 million (H1 2019: CHF 25.0 million), while the operating profit margin was unchanged at 18.6% of sales (H1 2019: 18.6%).
ADDITIONAL INFORMATION
REGIONAL DEVELOPMENT
The regional performance was significantly impacted by the COVID-19 pandemic overall and the timing of the onset in different parts of the world.
In Europe, Tecan's sales in the first six months of 2020 increased by 6.0% in local currencies and by 3.3% in Swiss francs. The increase in sales was driven by the Life Sciences Business, with various larger instrument installations supporting PCR-based testing as part of the European COVID-19 response. Sales of the Partnering Business declined in Europe as several customers suffered from the decrease in doctor visits and related lower volumes in routine diagnostic testing as well as restricted access to labs.
In North America, sales in the first six months of 2020 rose by 2.9% in local currencies and by 0.1% in Swiss francs. The Partnering Business delivered double-digit revenue growth, mainly supplying platforms, components and disposable pipette tips for molecular coronavirus testing. By contrast, sales in the Life Sciences Business declined in the first half of the year as the local business suffered from closed facilities and restricted access to labs to perform instrument installations. However, demand for higher throughput automation systems accelerated substantially in the course of the second quarter in North America, and the Life Sciences Business recorded a double-digit increase in order entry for the first half of the year.
In Asia, Tecan recorded a significant increase in sales of 25.3% in local currencies and 18.4% in Swiss francs. This increase was driven by double-digit growth rates in both business segments. From as early as the beginning of the year, Tecan started to support local in-vitro diagnostic companies in China and South Korea, existing customers of the Partnering Business, with automation platforms for PCR-basedCOVID-19 testing. The Life Sciences Business performed particularly well in Australia and, when quarantines and lockdown measures started to be eased, also saw accelerating demand for its product portfolio in other markets in the Asia-Pacific
region. Of particular note was the sales growth of Tecan in China, which outpaced that of the Asia region as a whole.
OPERATING HIGHLIGHTS
IN THE FIRST HALF OF 2020
During the first half of the year, all priorities were focused on ensuring the health and safety of Tecan employees, limiting any supply chain and freight interruptions and maintaining business continuity to support customers in these challenging times.
At the beginning of the year, efforts to keep Tecan associates safe were first focused on the China team. As COVID-19 spread to other parts of the world in the second quarter, the company quickly adopted a global "work from home" policy and significantly restricted travel. Tecan also activated its Pandemic Plan and implemented various measures and safety protocols at all sites to protect employees and keep business operations running.
To ensure a continued flow of goods and production, a COVID-19 task force was set up to diligently monitor the supplier base from the beginning of the outbreak. Products were categorized based on criticality of material availability, and stocking levels were maintained or increased as appropriate. All manufacturing sites introduced shift operations and production teams were segregated and separated to work in smaller, isolated groups. Through the implementation of these measures, Tecan continued to be fully operational at all production sites and provided undisrupted support to customers.
In anticipation of increased COVID-19 clinical testing and high customer demand associated with the global pandemic, Tecan took a number of steps to secure supplies of materials and expand capacity and supply for specific product lines, including certain instrument platforms and disposable pipette tips.
At the same time, Tecan continued to invest in research and development to position the business for sustained accelerated growth. Earlier in the year, Tecan launched the DreamPrep™ NAP, an inte- grated, fully automated solution simplifying nucleic acid extraction workflows. It combines the high productivity and precision of the Fluent automation platform with a Tecan Infinite 200 reader for integrated quantitation and normalization as well as dedicated reagents from a partner company. The DreamPrep NAP is also well positioned to help labs quickly and effectively scale up COVID-19 testing to accommodate larger test volumes.
Tecan also made good progress with a number of ongoing development projects in the Partnering Business.
Tecan Interim Report 2020 | 5 |
Letter to the Shareholders
STRONG BALANCE SHEET -
HIGH EQUITY RATIO
Tecan's equity ratio was 69.8% as of June 30, 2020 (December 31, 2019: 70.1%). Net liquidity (cash and cash equivalents plus short- term time deposits minus bank liabilities and loans) reached CHF 354.0 million (June 30, 2019: CHF 264.5 million; Decem- ber 31, 2019: CHF 312.4 million). At the Tecan Group Annual General Meeting on April 7, 2020, shareholders approved an increase in the dividend from CHF 2.10 to CHF 2.20 per registered share. Half of the dividend, i.e. CHF 1.10, was paid out from the available capital contribution reserve and was therefore not subject to withholding tax. The payout took place on April 15, 2020.
At the same time, Tecan now expects a reported EBITDA margin in fiscal year 2020 closer to 20% of sales (previously "reported EBIT- DA margin of around 19.6% of sales"), despite a worsening of the currency environment. The revised forecasts for average exchange rates in full-year 2020 now assume one US dollar equaling CHF 0.95 (previously CHF 0.98) and one euro equaling CHF 1.08 (un- changed), leading to a negative foreign exchange rate impact that is already factored into the updated outlook.
The outlook 2020 does not take account of potential acquisitions during the course of the year.
OUTLOOK FOR FULL-YEAR 2020 RAISED
Based on the positive business performance in the first six months | |
of 2020, as well as on the high order backlog and the anticipated | |
demand in the second half of the year, Tecan raised its outlook for | DR. LUKAS BRAUNSCHWEILER |
full-year 2020. Due to the ongoing pandemic, this outlook is still | Chairman of the Board |
subject to greater uncertainty than usual. In particular, these up- | |
dated projections are based on the assumptions that supply chains | |
remain undisrupted and all production sites stay fully operational. | |
Tecan now forecasts sales growth for full-year 2020 to be in the high | |
single-digit percentage range in local currencies (previously "mid- to | DR. ACHIM VON LEOPRECHTING |
high single-digit percentage range"). | Chief Executive Officer |
6 Tecan Interim Report 2020
Interim condensed consolidated financial statements as of June 30, 2020
INTERIM CONSOLIDATED STATEMENT OF PROFIT OR LOSS
Notes | 2019 | 2020 | |
January to June, CHF 1,000 | |||
Sales | 4, 5 | 296,120 | 310,004 |
Cost of sales | (155,145) | (163,900) | |
Gross profit | 140,975 | 146,104 | |
Sales and marketing | (46,891) | (48,593) | |
Research and development | (29,550) | (25,322) | |
General and administration | (31,544) | (29,560) | |
Other operating income | 270 | 247 | |
Other operating expenses | (275) | (252) | |
Operating profit | 5 | 32,985 | 42,624 |
Financial income | 14 | 16 | |
Finance cost | (790) | (656) | |
Net foreign exchange losses | (2,106) | (650) | |
Financial result | (2,882) | (1,290) | |
Profit before taxes | 30,103 | 41,334 | |
Income taxes | 7 | (4,765) | (5,296) |
Profit for the period, attributable to owners of the parent | 25,338 | 36,038 | |
Earnings per share | |||
Basic earnings per share (CHF/share) | 2.14 | 3.02 | |
Diluted earnings per share (CHF/share) | 2.13 | 3.01 | |
INTERIM CONSOLIDATED STATEMENT OF PROFIT OR LOSS AND OTHER COMPREHENSIVE INCOME
Notes | 2019 | 2020 | |
January to June, CHF 1,000 | |||
Profit for the period | 25,338 | 36,038 | |
Other comprehensive income | |||
Change in fair value and sale of an unquoted equity instrument | 3.2 | (1,000) | 1,588 |
Related income taxes | 78 | (318) | |
Remeasurement of net defined benefit liability | (11,886) | (1,196) | |
Related income taxes | 1,973 | 223 | |
Items that will not be reclassified to profit or loss, | |||
net of income taxes | (10 835) | 297 | |
Translation differences | 10 | (2,058) | (3,951) |
Related income taxes | 31 | 61 | |
Items that may be reclassified subsequently to profit or loss, | |||
net of income taxes | (2,027) | (3,890) | |
Other comprehensive loss, net of income taxes | (12,862) | (3,593) | |
Total comprehensive income for the period, | |||
attributable to owners of the parent | 12,476 | 32,445 | |
Tecan Interim Report 2020 | 7 |
Interim condensed consolidated financial statements as of June 30, 2020
INTERIM CONSOLIDATED BALANCE SHEET
ASSETS
Notes | 31.12.2019 | 30.06.2020 | |
CHF 1,000 | |||
Cash and cash equivalents | 266,274 | 189,677 | |
Other current financial assets | 50,500 | 170,906 | |
Trade accounts receivable | 121,517 | 96,366 | |
Contract assets | 468 | 645 | |
Other accounts receivable | 12,159 | 15,026 | |
Inventories | 8 | 151,947 | 162,924 |
Income tax receivables | 3,098 | 3,970 | |
Prepaid expenses | 6,536 | 8,236 | |
Assets held for sale | 3,000 | - | |
Current assets | 615,499 | 647,750 | |
Non-current financial assets | 11 | 1,173 | 1,018 |
Investment property | 3,428 | 3,317 | |
Property, plant and equipment | 29,393 | 29,394 | |
Right-of-use assets | 43,428 | 40,704 | |
Intangible assets and goodwill | 222,965 | 223,050 | |
Deferred tax assets | 23,887 | 23,350 | |
Non-current assets | 324,274 | 320,833 | |
Assets | 939,773 | 968,583 | |
LIABILITIES AND EQUITY
Notes | 31.12.2019 | 30.06.2020 | |
CHF 1,000 | |||
Current financial liabilities | 11 | 14,682 | 15,584 |
Trade accounts payable | 10,403 | 16,985 | |
Other accounts payable | 16,717 | 20,039 | |
Current contract liabilities | 36,222 | 45,544 | |
Income tax payables | 14,404 | 12,529 | |
Accrued expenses | 45,153 | 43,785 | |
Current provisions | 19,705 | 19,116 | |
Current liabilities | 157,286 | 173,582 | |
Non-current financial liabilities | 11 | 34,484 | 31,804 |
Non-current contract liabilities | 25,947 | 24,535 | |
Liability for post-employment benefits | 51,881 | 52,286 | |
Non-current provisions | 5,301 | 5,319 | |
Deferred tax liabilities | 5,807 | 5,080 | |
Non-current liabilities | 123,420 | 119,024 | |
Total liabilities | 280,706 | 292,606 | |
Share capital | 1,187 | 1,194 | |
Capital reserve | 43,434 | 45,535 | |
Retained earnings | 650,085 | 668,777 | |
Translation differences | (35,639) | (39,529) | |
Shareholders' equity | 9 | 659,067 | 675,977 |
Liabilities and equity | 939,773 | 968,583 | |
- Tecan Interim Report 2020
Interim condensed consolidated financial statements as of June 30, 2020
INTERIM CONSOLIDATED STATEMENT OF CASH FLOWS
Notes | 2019 | 2020 | |
January to June, CHF 1,000 | |||
Profit for the period | 25,338 | 36,038 | |
Adjustments for | |||
Depreciation and amortization | 16,314 | 17,542 | |
Change in provisions and liability for post-employment benefits | (2,100) | (1,042) | |
Interest income | (14) | (16) | |
Interest expenses | 587 | 456 | |
Income taxes | 4,765 | 5,296 | |
Equity-settledshare-based payment transactions | 10,762 | 8,030 | |
Other non-cash items | (180) | 1,649 | |
Change in working capital | |||
Trade accounts receivable | 5,592 | 23,432 | |
Inventories | 8 | (112) | (12,251) |
Trade accounts payable | (3,963) | 6,703 | |
Contract liabilities | (3,116) | 8,687 | |
Other changes in working capital (net) | (11,798) | (3,723) | |
Settlement of contingent consideration | (800) | - | |
Income taxes paid | (5,306) | (7,959) | |
Cash inflows from operating activities | 35,969 | 82,842 | |
Investment in time deposits | - | (120,000) | |
Sale of an unquoted equity investment | 3.2 | - | 4,588 |
Interest received | 14 | 14 | |
Acquisition of DCPM/PMAS, net of cash acquired | 3.1 | (21,226) | - |
Settlement of contingent consideration | (4,200) | - | |
Purchase of property, plant and equipment | (4,712) | (4,972) | |
Proceeds from sale of property, plant and equipment | 38 | 5 | |
Investment in intangible assets | (6,635) | (10,242) | |
Cash outflows from investing activities | (36,721) | (130,607) | |
Proceeds from employee participation plans | 1,170 | 2,108 | |
Dividends paid | 9.2 | (24,835) | (26,242) |
Payment of lease liabilities | (4,860) | (5,217) | |
Increase in/repayment of short-term credit facilities | 2,299 | 3,001 | |
Increase in bank loans | 568 | 239 | |
Repayment of bank loans | - | (1,397) | |
Interest paid | (430) | (454) | |
Cash outflows from financing activities | (26,088) | (27,962) | |
Effect of exchange rate fluctuations on cash held | (303) | (870) | |
Decrease in cash and cash equivalents | (27,143) | (76,597) | |
Cash and cash equivalents, net of bank overdrafts at January 1 | 296,836 | 266,274 | |
Cash and cash equivalents, net of bank overdrafts at June 30 | 269,693 | 189,677 | |
Tecan Interim Report 2020 | 9 |
Interim condensed consolidated financial statements as of June 30, 2020
INTERIM CONSOLIDATED STATEMENT OF CHANGES IN EQUITY
Notes | Share | Capital | Retained | Translation | Total share- | |
capital | reserve | earnings | differences | holders' equity | ||
January to June, CHF 1,000 | ||||||
Balance at January 1, 2019 | 1,177 | 38,861 | 602,820 | (30,449) | 612,409 | |
Profit for the period | - | - | 25,338 | - | 25,338 | |
Other comprehensive loss, | ||||||
net of income taxes | - | - | (10,835) | (2,027) | (12,862) | |
Total comprehensive income for the period | - | - | 14,503 | (2,027) | 12,476 | |
Dividends paid | - | - | (24,835) | - | (24,835) | |
New shares issued based on | ||||||
employee participation plans | 8 | 1,162 | - | - | 1,170 | |
Share-based payments, | ||||||
net of income taxes | - | - | 11,428 | - | 11,428 | |
Total contributions by and distributions | ||||||
to owners | 9 | 8 | 1,162 | (13,407) | - | (12,237) |
Balance at June 30, 2019 | 1,185 | 40,023 | 603,916 | (32,476) | 612,648 | |
Balance at January 1, 2020 | 1,187 | 43,434 | 650,085 | (35,639) | 659,067 | |
Profit for the period | - | - | 36,038 | - | 36,038 | |
Other comprehensive loss, | ||||||
net of income taxes | - | - | 297 | (3,890) | (3,593) | |
Total comprehensive income for the period | - | - | 36,335 | (3,890) | 32,445 | |
Dividends paid | - | - | (26,242) | - | (26,242) | |
New shares issued based on | ||||||
employee participation plans | 7 | 2,101 | - | - | 2,108 | |
Share-based payments, | ||||||
net of income taxes | - | - | 8,599 | - | 8,599 | |
Total contributions by and distributions | ||||||
to owners | 9 | 7 | 2,101 | (17,643) | - | (15,535) |
Balance at June 30, 2020 | 1,194 | 45,535 | 668,777 | (39,529) | 675,977 | |
10 Tecan Interim Report 2020
Interim condensed consolidated financial statements as of June 30, 2020
Notes to the interim condensed consolidated financial statements
- REPORTING ENTITY
The Tecan Group is a global provider of automated laboratory instruments and solutions in biopharmaceuticals, forensics and clinical diagnostics. The Group specializes in the development, production, marketing and support of automated workflow solutions for laboratories in the life sciences sector. Its clients include pharmaceutical and biotechnology companies, university research departments, forensic and diagnostic laboratories. As an original equipment manufacturer, the Group also develops and manufactures OEM instruments and components that are then distributed by partner companies. Founded in Switzerland in 1980, the Group has manufacturing, research and development sites in both Europe and North America and maintains a sales and service network in 52 countries.
The ultimate parent company is Tecan Group Ltd., a limited company incorporated in Switzerland, whose shares are publicly traded. Tecan Group Ltd.'s registered office is located at Seestrasse 103, 8708 Männedorf, Switzerland.
2 BASIS OF PREPARATION AND SIGNIFICANT ACCOUNTING POLICIES
2.1 BASIS OF PREPARATION
These unaudited financial statements are the interim condensed consolidated financial statements of Tecan Group Ltd. and its subsidiaries (together referred to as the 'Group') for the six-month period ending June 30, 2020. The financial statements are prepared in accordance with International Accounting Standard (IAS) 34 'Interim Financial Reporting' and should be read in conjunction with the consolidated financial statements 2019 as they provide an update of previously reported information. The interim condensed consolidated financial statements were authorized for issue on August 10, 2020.
The preparation of these interim condensed consolidated financial statements requires management to make assumptions and estimates that affect the reported amounts of revenues, expenses, assets, liabilities and disclosure of contingent liabilities at the date of these interim condensed consolidated financial statements. If in the future such assumptions and estimates deviate from the actual circumstances, the original assumptions and estimates will be modified as appropriate in the period in which the circumstances change.
The Group operates in industries where significant seasonal or cyclical variations in total sales are not experienced during the financial year.
Income tax expense is recognized based on the best estimate of the weighted average annual income tax rate expected for the full financial year.
2.2 COVID-19 PANDEMIC
The global health and economic crisis resulting from the COVID-19 pandemic affects the Group in its day-to-day operations. The related impacts encompass a significant change in product mix as well as cost effects. For example, with numerous laboratories closed in most of the countries, the local service teams had no or only limited access to the customers sites particularly in April and May. Therefore, the service cost center was showing higher under- absorption, reflecting the under-utilization of the installation and service department. In addition, the Group had to accept higher freight costs caused by the partial cessation of flight operations and other restrictions on international trade. Also, an increase in safety stocks was required to limit the impact of any supply chain interruptions for production. On the other hand, travel spend went down, partly offsetting the adverse costs mentioned above.
The Group has also seen a significant increase in order entry due to higher demand mainly for Liquid Handling instruments and respective consumables as a result of the pandemic. This led to increased sales albeit with significant shifts in the product mix due to changes in the business environment of its customers.
2.3 INTRODUCTION OF NEW AND REVISED/AMENDED STANDARDS AND INTERPRETATIONS
The accounting policies used in the preparation of the interim condensed consolidated financial statements are consistent with those followed in the preparation of the consolidated financial statements 2019, except for the adoption of the following new or revised/amended standards and interpretations, effective as from January 1, 2020:
Standard/interpretation1
Conceptual Framework for Financial Reporting
IAS 1 'Presentation of Financial Statements' amended and IAS 8 'Accounting Policies, Changes in Accounting Estimates and Errors' amended - Definition of Material
IFRS 3 'Business Combinations' amended - Definition of a Business
Interest Rate Benchmark Reform - Amendments to IFRS 9, IAS 39 and IFRS 7
IFRS 16 'Leases' amended - Covid-19-Related Rent Concessions (early application)
1 IAS = International Accounting Standards, IFRS = International Financial Reporting Standards, IFRIC = Interpretations as by the IFRS Interpretations Committee (formerly International Financial Reporting Interpretations Committee)
The adoption of the conceptual framework and amended standards did not result in substantial changes to the Group's accounting policies.
Tecan Interim Report 2020 | 11 |
Interim condensed consolidated financial statements as of June 30, 2020
2.4 NEW AND REVISED/AMENDED STANDARDS AND INTERPRETATIONS
NOT YET APPLIED
The following new and revised/amended standards and interpretations have been issued, but are not yet effective and are not applied early in these interim condensed consolidated financial statements:
Standard/interpretation1 | Effective date |
for the Group | |
IAS 16 'Property, Plant and Equipment' | Reporting year |
amended - Proceeds before Intended Use | 2022 |
IAS 37 'Provisions, Contingent Liabilities and | Reporting year |
Contingent Assets' amended - Onerous | 2022 |
Contracts (Cost of Fulfilling a Contract) | |
IFRS 3 'Business Combinations' amended - | Reporting year |
Reference to the Conceptual Framework | 2022 |
Annual Improvements to IFRS Standards | Reporting year |
2018 - 2020 | 2022 |
IAS 1 'Presentation of Financial Statements' | Reporting year |
amended - Classification of Liabilities as | 2023 |
Current or Non-current | |
IFRS 10 amended 'Consolidated Financial | To be defined |
Statements' and IAS 28 amended 'Investments | |
in Associates and Joint Ventures' - Sale or | |
Contribution of Assets between an Investor | |
and its Associate or Joint Venture | |
1 IAS = International Accounting Standards, IFRS = International Financial Reporting Standards, IFRIC = Interpretations as by the IFRS Interpretations Committee (formerly International Financial Reporting Interpretations Committee)
The changes, individually and in the aggregate, are not expected to have a significant impact on the balance sheet, results of operations and cash flows of the Group upon adoption.
12 Tecan Interim Report 2020
Interim condensed consolidated financial statements as of June 30, 2020
3 SCOPE OF CONSOLIDATION
3.1 INFORMATION ON ACQUISITION IN PREVIOUS YEAR - ACQUISITION OF DCPM/PMAS
The Group acquired 100% of the voting rights of a long-term supplier on May 31, 2019.The initial accounting for the acquisition of DCPM/PMAS was based on the assumption that the Group would take the election pursuant to section 338(h)(10) of the US tax law, under which a legal share deal is treated as an asset deal for tax purposes. Consequently, no deferred tax liabilities were recognized for the US entity DCPM in the interim report 2019.
However, after a detailed analysis, it was concluded that the election would not be advantageous for the Group. Accordingly, the opening balance of DCPM/PMAS was adjusted for deferred tax liabilities of CHF 2.1 million in the second half of 2019. The purchase price allocation is considered as completed.
The adjusted fair value of the identifiable assets and liabilities and the net cash outflow at the date of acquisition were:
31.05.2019 | |
DCPM/PMAS | |
CHF 1,000 | |
Cash and cash equivalents | 297 |
Trade accounts receivable (gross contractual value) | 1,106 |
Inventories | 3,225 |
Other current asset | 427 |
Property, plant and equipment | 4,670 |
Right-of-use assets | 2,961 |
Intangible assets | 5,599 |
Deferred tax assets | 53 |
Assets | 18,338 |
Current financial liabilities | (448) |
Trade and other accounts payable | (2,799) |
Income tax payable | (10) |
Accrued expenses and current provisions | (850) |
Non-current financial liabilities | (2,513) |
Deferred tax liabilities | (2,096) |
Liabilities | (8,716) |
Total identifiable net assets at fair value | 9,622 |
Goodwill arising on acquisition | 11,521 |
Consideration transferred for the business combination | 21,143 |
Cash acquired | (297) |
Deferred closing adjustment (receivable) | 380 |
Net cash outflow (including holdback) | 21,226 |
The holdback of USD 3.0 million that was paid into an escrow account upon acquisition, was released to the seller beginning of June 2020 without any deductions.
3.2 DISPOSAL GROUP HELD FOR SALE 'UNQUOTED EQUITY INSTRUMENT'
Towards the end of 2019 the management started sales negotiations for the unquoted equity instrument. Therefore, the financial asset of CHF 3.0 million was classified as held for sale at year-end 2019. The Group continued to measure the investment at fair value through other comprehensive income (FVOCI) in accordance with IFRS 9 using the discounted cash flow method with level 3 inputs of the fair value hierarchy.
In January 2020, the Group signed a final share purchase agreement with a total estimated consideration of CHF 4.6 million. The gain from this transaction of CHF 1.6 million was recognized in other comprehensive income of 2020.
Tecan Interim Report 2020 | 13 |
Interim condensed consolidated financial statements as of June 30, 2020
4 REVENUE FROM CONTRACTS WITH CUSTOMERS
4.1 DISAGGREGATION OF REVENUE AND RECONCILIATION TO SEGMENT INFORMATION
Life Sciences Business | Partnering Business | Total 2019 | ||||||||
Revenue | Leases | Sales | Revenue | Leases | Sales | Revenue | Leases | Total | ||
contracts | segment | contracts | segment | contracts | sales | |||||
with | with | with | ||||||||
customers | customers | customers | ||||||||
January to June, CHF 1,000 | ||||||||||
By regions (location of customer) | ||||||||||
Europe | 50,942 | 452 | 51,394 | 70,174 | - | 70,174 | 121,116 | 452 | 121,568 | |
Americas | 78,319 | - | 78,319 | 45,380 | - | 45,380 | 123,699 | - | 123,699 | |
Asia | 29,334 | - | 29,334 | 17,097 | - | 17,097 | 46,431 | - | 46,431 | |
Others | 3,324 | - | 3,324 | 1,098 | - | 1,098 | 4,422 | - | 4,422 | |
Total | 161,919 | 452 | 162,371 | 133,749 | - | 133,749 | 295,668 | 452 | 296,120 | |
By products and services | ||||||||||
Products | 125,944 | - | 125,944 | 106,203 | - | 106,203 | 232,147 | - | 232,147 | |
Services | 35,975 | - | 35,975 | 27,546 | - | 27,546 | 63,521 | - | 63,521 | |
Leases | - | 452 | 452 | - | - | - | - | 452 | 452 | |
Total | 161,919 | 452 | 162,371 | 133,749 | - | 133,749 | 295,668 | 452 | 296,120 | |
By timing of revenue recognition | ||||||||||
Transferred at a point in time | 137,215 | - | 137,215 | 126,646 | - | 126,646 | 263,861 | - | 263,861 | |
Transferred over time | 24,704 | - | 24,704 | 7,103 | - | 7,103 | 31,807 | - | 31,807 | |
Leases | - | 452 | 452 | - | - | - | - | 452 | 452 | |
Total | 161,919 | 452 | 162,371 | 133,749 | - | 133,749 | 295,668 | 452 | 296,120 | |
Life Sciences Business | Partnering Business | Total 2020 | ||||||||
Revenue | Leases | Sales | Revenue | Leases | Sales | Revenue | Leases | Total | ||
contracts | segment | contracts | segment | contracts | sales | |||||
with | with | with | ||||||||
customers | customers | customers | ||||||||
January to June, CHF 1,000 | ||||||||||
By regions (location of customer) | ||||||||||
Europe | 61,231 | 508 | 61,739 | 63,843 | - | 63,843 | 125,074 | 508 | 125,582 | |
Americas | 72,425 | - | 72,425 | 51,437 | - | 51,437 | 123,862 | - | 123,862 | |
Asia | 31,014 | - | 31,014 | 23,981 | - | 23,981 | 54,995 | - | 54,995 | |
Others | 4,183 | - | 4,183 | 1,382 | - | 1,382 | 5,565 | - | 5,565 | |
Total | 168,853 | 508 | 169,361 | 140,643 | - | 140,643 | 309,496 | 508 | 310,004 | |
By products and services | ||||||||||
Products | 131,225 | - | 131,225 | 115,574 | - | 115,574 | 246,799 | - | 246,799 | |
Services | 37,628 | - | 37,628 | 25,069 | - | 25,069 | 62,697 | - | 62,697 | |
Leases | - | 508 | 508 | - | - | - | - | 508 | 508 | |
Total | 168,853 | 508 | 169,361 | 140,643 | - | 140,643 | 309,496 | 508 | 310,004 | |
By timing of revenue recognition | ||||||||||
Transferred at a point in time | 142,666 | - | 142,666 | 132,831 | - | 132,831 | 275,497 | - | 275,497 | |
Transferred over time | 26,187 | - | 26,187 | 7,812 | - | 7,812 | 33,999 | - | 33,999 | |
Leases | - | 508 | 508 | - | - | - | - | 508 | 508 | |
Total | 168,853 | 508 | 169,361 | 140,643 | - | 140,643 | 309,496 | 508 | 310,004 | |
14 Tecan Interim Report 2020
Interim condensed consolidated financial statements as of June 30, 2020
5 SEGMENT INFORMATION
5.1 SEGMENT INFORMATION BY BUSINESS SEGMENTS
Life Sciences | Partnering | Corporate/ | Group | |||||
Business | Business | consolidation | ||||||
2019 | 2020 | 2019 | 2020 | 2019 | 2020 | 2019 | 2020 | |
January to June, CHF 1,000 | ||||||||
Sales to third parties | 162,371 | 169,361 | 133,749 | 140,643 | - | - | 296,120 | 310,004 |
Intersegment sales | 6,971 | 9,379 | 718 | 745 | (7,689) | (10,124) | - | - |
Total sales | 169,342 | 178,740 | 134,467 | 141,388 | (7,689) | (10,124) | 296,120 | 310,004 |
Operating profit | 18,960 | 22,466 | 25,036 | 26,316 | (11,011) | (6,158) | 32,985 | 42,624 |
Depreciation and amortization | (11,397) | (11,179) | (4,917) | (6,363) | - | - | (16,314) | (17,542) |
2019 | 2020 | |
January to June, CHF 1,000 | ||
Reconciliation of reportable segment sales | ||
Total sales for reportable segments | 303,809 | 320,128 |
Elimination of intersegment sales | (7,689) | (10,124) |
Total consolidated sales | 296,120 | 310,004 |
Reconciliation of reportable segment profit | ||
Total operating profit for reportable segments | 43,996 | 48,782 |
Unallocated costs (business development, investor relations and other corporate costs) | ||
and consolidation entries | (11,011) | (6,158) |
Financial result | (2,882) | (1,290) |
Total consolidated profit before taxes | 30,103 | 41,334 |
5.2 ENTITY-WIDE DISCLOSURES
Non-current assets by regions (by location of assets)
Property, plant and equipment | Right-of-use assets | Intangible assets | ||||
31.12.2019 | 30.06.2020 | 31.12.2019 | 30.06.2020 | 31.12.2019 | 30.06.2020 | |
CHF 1,000 | ||||||
Switzerland | 14,402 | 14,861 | 19,828 | 20,812 | 104,130 | 106,821 |
Other Europe | 5,605 | 5,447 | 7,352 | 6,072 | 7,651 | 7,001 |
North America | 7,124 | 7,018 | 13,075 | 11,070 | 111,184 | 109,228 |
Asia | 2,262 | 2,068 | 3,173 | 2,750 | - | - |
Total | 29,393 | 29,394 | 43,428 | 40,704 | 222,965 | 223,050 |
Information about major customers
There are sales to one individual customer (CHF 32.6 million) relating to the business segment Partnering Business that in aggregate exceeded 10% of total sales in the first half of 2020 (first half of
2019: one individual customer [CHF 37.0 million] relating to the business segment Partnering Business that in aggregate exceeded 10% of total sales).
Tecan Interim Report 2020 | 15 |
Interim condensed consolidated financial statements as of June 30, 2020
6 | OPERATING EXPENSES BY NATURE | ||
2019 | 2020 | ||
January to June, CHF 1,000 | |||
Material costs | 100,398 | 101,724 | |
Personnel costs | 112,873 | 121,121 | |
Depreciation of property, plant and equipment | 4,072 | 4,729 | |
Depreciation of right-of-use assets | 5,148 | 5,457 | |
Amortization of intangible assets | 7,094 | 7,356 | |
Other operating costs | 41,177 | 37,755 | |
Total operating cost incurred (gross) | 270,762 | 278,142 | |
Capitalization of development costs in position inventories | (2,179) | (1,225) | |
Capitalization of development costs in position intangible assets | (5,178) | (9,290) | |
Other operating income | (270) | (247) | |
Total operating expenses, according to statement of profit or loss | 263,135 | 267,380 | |
In April 2020 the Swiss pension plan was adjusted. The conversion rate used to calculate the annuity relating to the exceeding part of savings capital will be reduced, starting from January 1, 2022. This modification is considered a plan amendment. The resulting positive
past service costs amounting to CHF 2.2 million were recognized immediately in profit or loss and are included in the personnel costs of 2020.
7 INCOME TAXES - SWISS TAX REFORM
On May 19, 2019, the Swiss electorate passed the Federal Act on Tax Reform and AHV Financing (TRAF). The tax reform abolishes the tax regimes for holding, domiciliary and mixed companies as of January 1, 2020 and introduces new tax measures. To the extent that the tax reform requires cantonal and communal tax law changes, these have to be implemented through modification of the cantonal tax law. On September 1, 2019, in a public vote, the electorate of the canton of Zurich accepted the respective revision of the cantonal tax law. The relevant changes to the Group include
a decrease in the statutory income tax rate in the canton of Zurich, effective as from January 1, 2021.
As part of the TRAF and cantonal tax practice, transitional measures were introduced in order to ease the transition from the current reliefs to the new tax measures. For the Group, these measures allow amongst others the tax-effective amortization of a step-up amount over a period of up to 10 years. As a consequence, the Group started to capitalize corresponding deferred tax assets in 2019.
Deferred tax assets capitalized in connection with the step-up amount:
2020 | |
CHF 1,000 | |
Balance at January 1 | 3,635 |
Write-off deferred tax asset for corresponding tax benefits received in current period | (363) |
Recognition of deferred tax assets for tax benefits in future periods (non-recurring) | 1,817 |
Balance at June 30 | 5,089 |
The calculation of the deferred tax assets related to the Swiss tax reform required management to make significant estimates and
assumptions. The final outcome is still uncertain and might lead to adjustments in future years.
16 Tecan Interim Report 2020
Interim condensed consolidated financial statements as of June 30, 2020
- INVENTORIES
In 2010, the Group entered into an OEM agreement with a global diagnostics company. The agreement comprises the development and supply of a dedicated diagnostic instrument. The related customer-specific development costs were capitalized in the position inventories as part of the production costs. The delivery of the instruments, which takes place over a period of more than 10 years, started in October 2014. The customer requests the units with individual purchase orders. The Group recognizes the correspond-
ing development costs in cost of sales upon fulfilment of the individual purchase orders. The remaining balance of capitalized development costs amounted to CHF 59.1 million at the end of June 2020 (December 31, 2019: CHF 65.3 million).
Further information regarding this critical accounting estimate and judgment can be found in note 2.2.4 of the consolidated financial statements 2019.
- SHAREHOLDERS' EQUITY AND EMPLOYEE PARTICIPATION PLANS
9.1 MOVEMENTS IN SHARES OUTSTANDING
Shares | Treasury | Shares | |
issued | shares | outstanding | |
Shares (each share has a nominal value of CHF 0.10) | |||
Balance at January 1, 2019 | 11,766,372 | - | 11,766,372 |
New shares issued based on employee participation plans | 82,109 | - | 82,109 |
Balance at June 30, 2019 | 11,848,481 | - | 11,848,481 |
Balance at January 1, 2020 | 11,870,912 | - | 11,870,912 |
New shares issued based on employee participation plans | 74,420 | - | 74,420 |
Balance at June 30, 2020 | 11,945,332 | - | 11,945,332 |
9.2 | DIVIDENDS PAID | ||
2019 | 2020 | ||
Number of shares eligible for dividend and payout | 11,826,232 | 11,927,914 | |
Dividends paid (CHF/share) | 2.10 | 1.10 | |
Payout from statutory capital contribution reserve (CHF/share) | - | 1.10 | |
9.3 | CONDITIONAL SHARE CAPITAL RESERVED FOR THE EMPLOYEE PARTICIPATION PLANS | ||
2019 | 2020 | ||
Shares (each share has a nominal value of CHF 0.10) | |||
Balance at January 1 | 536,840 | 432,300 | |
New shares issued based on employee participation plans | (82,109) | (74,420) | |
Balance at June 30 | 454,731 | 357,880 | |
Maximum of employee share options and employee shares outstanding | 228,080 | 184,109 | |
Tecan Interim Report 2020 | 17 |
Interim condensed consolidated financial statements as of June 30, 2020
9.4 CONDITIONAL AND AUTHORIZED SHARE CAPITAL FOR THE PURPOSE OF
FUTURE BUSINESS DEVELOPMENT
2019 | 2020 | |
Conditional share capital | ||
Shares (with a nominal value of CHF 0.10 each) | 1,800,000 | 1,800,000 |
CHF | 180,000 | 180,000 |
Authorized share capital | ||
Expiry date | 17.04.2020 | 17.04.2022 |
Shares (with a nominal value of CHF 0.10 each) | 2,300,000 | 2,300,000 |
CHF | 230,000 | 230,000 |
9.5 EMPLOYEE SHARE OPTION PLANS
(See note 12.4.1 of the consolidated financial statements 2019 for the terms and principal conditions)
Movements in employee share options:
2019 | 2020 | |
Employee share options | ||
Balance at January 1 | 90,040 | 91,524 |
Granted | 12,900 | - |
Exercised | (9,834) | (12,745) |
Forfeited or expired | (1,364) | (1,615) |
Balance at June 30 | 91,742 | 77,164 |
Thereof exercisable at period-end | 31,276 | 25,016 |
9.6 EMPLOYEE SHARE PLANS (PERFORMANCE SHARE MATCHING PLANS [PSMP] AND OTHER SHARE PLANS)
(See note 12.4.2 of the consolidated financial statements 2019 for the terms and principal conditions)
Movements in employee shares:
2019 | 2020 | |||
Employee shares | ||||
Balance at January 1 | 192,314 | 169,744 | ||
PSMP Management | Plan 2015 and 2016 | Matching shares vested and transferred | (52,382) | (47,356) |
PSMP Management | New plan current year | Initial shares transferred (blocked) | 18,176 | 12,733 |
PSMP Management | New plan current year | Maximum of matching shares granted | 40,095 | 30,088 |
PSMP Management | All plans | Matching shares forfeited | 6 | (10,758) |
PSMP Management | All plans | Shares deblocked | - | (78) |
Board of Directors | Plan 2017 and 2018 | Shares vested and transferred | (1,717) | (1,586) |
Board of Directors | New plan current year | Shares granted | 1,684 | 1,323 |
Balance at June 30 | 198,176 | 154,110 | ||
Thereof vested and transferred, but blocked until the end of the performance period | 61,838 | 47,165 | ||
18 Tecan Interim Report 2020
Interim condensed consolidated financial statements as of June 30, 2020
10 | PRINCIPAL EXCHANGE RATES | ||||
Closing exchange rates | Average exchange rates | ||||
January to June | |||||
31.12.2019 | 30.06.2020 | 2019 | 2020 | ||
CHF | |||||
EUR | 1 | 1.09 | 1.06 | 1.13 | 1.06 |
USD | 1 | 0.97 | 0.95 | 1.00 | 0.97 |
11 FINANCIAL INSTRUMENTS AND FAIR VALUE DISCLOSURES
11.1 CLASSES OF FINANCIAL INSTRUMENTS
Cash | Other | Trade | Non-current | Total | Current | Trade and | Non-current | Total | |
and cash | current | and other | financial | assets | financial | other | financial | liabilities | |
equivalents | financial | receivables | assets | 2019 | liabilities | payables/ | liabilities | 2019 | |
assets | accrued | ||||||||
expenses | |||||||||
CHF 1,000 | |||||||||
Financial instruments measured at | |||||||||
fair value through P&L (FVTPL) | |||||||||
Currency forwards and options | - | 500 | - | 149 | 649 | (1,274) | - | (8) | (1,282) |
Financial instruments measured | |||||||||
at amortized costs1 | |||||||||
Cash and cash equivalents | 266,274 | - | - | - | 266,274 | - | - | - | - |
Time deposits | - | 50,000 | - | - | 50,000 | - | - | - | - |
Receivables | - | - | 121,775 | - | 121,775 | - | - | - | - |
Rent and other deposits | - | - | 656 | 1,024 | 1,680 | - | - | - | - |
Current bank liabilities | - | - | - | - | - | (2,153) | - | - | (2,153) |
Bank loans | - | - | - | - | - | (1,425) | - | (339) | (1,764) |
Payables and accrued expenses | - | - | - | - | - | - | (55,893) | - | (55,893) |
Other | |||||||||
Lease liabilities | - | - | - | - | - | (9,830) | - | (34,137) | (43,967) |
Total financial instruments | 266,274 | 50,500 | 122,431 | 1,173 | 440,378 | (14,682) | (55,893) | (34,484) | (105,059) |
Reconciling items2 | - | - | 11,245 | - | 11,245 | - | (16,380) | - | (16,380) |
Balance at December 31, 2019 | 266,274 | 50,500 | 133,676 | 1,173 | 451,623 | (14,682) | (72,273) | (34,484) | (121,439) |
1 The carrying amount of financial instruments measured at amortized costs is a reasonable approximation of their fair value due to their short-term nature. Bank loans are the only exception due to their long-term nature (fair value of TCHF 1'757).
- Receivables/payables arising from VAT/other non-income taxes and social security.
Tecan Interim Report 2020 | 19 |
Interim condensed consolidated financial statements as of June 30, 2020
Cash | Other | Trade | Non-current | Total | Current | Trade | Non-current | Total | |
and cash | current | and other | financial | assets | financial | and other | financial | liabilities | |
equivalents | financial | receivables | assets | 2020 | liabilities | payables/ | liabilities | 2020 | |
assets | accrued | ||||||||
expenses | |||||||||
CHF 1,000 | |||||||||
Financial instruments measured at | |||||||||
fair value through P&L (FVTPL) | |||||||||
Currency forwards and options | - | 906 | - | 13 | 919 | (175) | - | (16) | (191) |
Financial instruments | |||||||||
measured at amortized costs1 | |||||||||
Cash and cash equivalents | 189,677 | - | - | - | 189,677 | - | - | - | - |
Time deposits | - | 170,000 | - | - | 170,000 | - | - | - | - |
Receivables | - | - | 96,524 | - | 96,524 | - | - | - | - |
Rent and other deposits | - | - | 616 | 1 005 | 1,621 | - | - | - | - |
Current bank liabilities | - | - | - | - | - | (5,154) | - | - | (5,154) |
Bank loans | - | - | - | - | - | - | - | (571) | (571) |
Payables and accrued expenses | - | - | - | - | - | - | (60,930) | - | (60,930) |
Other | |||||||||
Lease liabilities | - | - | - | - | - | (10,255) | - | (31,217) | (41,472) |
Total financial instruments | 189,677 | 170,906 | 97,140 | 1,018 | 458,741 | (15,584) | (60,930) | (31,804) | (108,318) |
Reconciling items2 | - | - | 14,252 | - | 14,252 | - | (19,879) | - | (19,879) |
Balance at June 30, 2020 | 189,677 | 170,906 | 111,392 | 1,018 | 472,993 | (15,584) | (80,809) | (31,804) | (128,197) |
1 The carrying amount of financial instruments measured at amortized costs is a reasonable approximation of their fair value due to their short-term nature. Bank loans are the only exception due to their long-term nature (fair value of TCHF 576).
- Receivables/payables arising from VAT/other non-income taxes and social security .
11.2 FAIR VALUE HIERARCHY (LEVEL) AND VALUATION TECHNIQUES USED
Position | Level | Data source | Model |
Currency forwards | Level 2 | Bloomberg | (Forward rate - [spot rate +/- forward points]) * amount in foreign currency |
Currency options | Level 2 | Bloomberg | Black-Scholes model |
Bank loans | Level 2 | Bloomberg | The fair value is estimated by discounting the future contractual cash |
flows at the current market interest rate that is available to the Group for | |||
similar financial instruments. | |||
There have been no transfers between the levels in 2019 and 2020.
12 SUBSEQUENT EVENTS
There were no events subsequent to the balance sheet date which would require adjustments to or disclosures in these interim condensed consolidated financial statements.
20 Tecan Interim Report 2020
Global
Sales office
R&D and manufacturing site
Countries served by distributors
TECAN GROUP | SALES AND SERVICE LOCATIONS | |
Corporate Headquarters | Australia + 61 7 3897 1616 | Netherlands + 31 18 34 48 17 4 |
Tecan Group Ltd. | Austria + 43 62 46 89 330 | Singapore + 65 644 41 886 |
Seestrasse 103 | Belgium + 32 15 42 13 19 | Spain + 34 93 490 01 74 |
CH-8708 Männedorf | China + 86 21 2898 6333 | Sweden + 46 31 75 44 000 |
Switzerland | France + 33 4 72 76 04 80 | Switzerland + 41 44 922 81 11 |
T + 41 44 922 88 88 | Germany + 49 79 51 94 170 | UK + 44 118 9300 300 |
F + 41 44 922 88 89 | Italy + 39 02 92 44 790 | USA + 1 919 361 5200 |
Japan + 81 44 556 73 11 | ROW + 41 44 922 81 25 |
MANUFACTURING AND DEVELOPMENT SITES
Tecan Switzerland Ltd. | Tecan Austria GmbH | Tecan Systems, Inc. | IBL International GmbH |
Seestrasse 103 | Untersbergstrasse 1a | 2450 Zanker Road | Flughafenstr. 52a |
CH-8708 Männedorf | A-5082 Grödig/ | San Jose | D-22335 Hamburg |
Switzerland | Salzburg, Austria | CA 95131, USA | Germany |
T + 41 44 922 81 11 | T + 43 62 46 89 330 | T + 1 408 953 3100 | T + 49 40 532 891 0 |
F + 41 44 922 81 12 | F + 43 62 46 72 770 | F + 1 408 953 3101 | F + 49 40 532 891 11 |
DCPM Co. Ltd. | DCPM Inc. | Tecan SP, Inc. | Tecan Genomics, Inc. |
Lot A-2A-CN | 885 Jarvis drive | PO Box 1608 | 900 Chesapeake Drive |
My Phuoc 3 Indust | Morgan Hill | Baldwin Park | Redwood City |
Ben Cat Town | CA 95037, USA | CA 91706, USA | CA 94063, USA |
Binh Duong | T +1 626 962 0010 | T + 1 888 654 6544 | |
Vietnam | F +1 626 962 5574 |
IMPRINT
Publisher | Project Lead/Editorial Team | All statements in this Interim Report not |
Tecan Group Ltd. | Tecan Group Ltd., Männedorf | referring to historical facts are predictions |
Seestrasse 103 | Martin Brändle | of the future and constitute no guarantee |
CH-8708 Männedorf | Senior Vice President, | whatsoever of future performance. They |
Switzerland | Corporate Communications & IR | are subject to risks and uncertainties |
T + 41 44 922 84 30 | including, but not limited to, future global | |
F + 41 44 922 88 89 | Design Concept and Realization | economic conditions, exchange rates, legal |
investor(at)tecan.com | W4 Marketing AG, Switzerland | regulations, market conditions, activities of |
www.tecan.com | UP THERE, EVERYWHERE, Sweden | competitors and other factors outside the |
Company's control. | ||
Images | ||
Tecan Group Ltd., Switzerland | This Interim Report is available in English | |
Adobe Stock | and German and can also be found at | |
the website www.tecan.com. For the | ||
Translation | Financial Report, the English report is the | |
Lionbridge, Switzerland | authoritative version. | |
Printing | ||
Printlink AG, | ||
Switzerland |
Tecan Group Ltd. Seestrasse 103 CH-8708 Männedorf Switzerland www.tecan.com
Attachments
- Original document
- Permalink
Disclaimer
Tecan Group AG published this content on 12 August 2020 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 12 August 2020 08:47:15 UTC